Abeona Therapeutics, Inc. (ABEO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.00+1.18%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — achieve EPS >= $1.71 by 2026-06-30: EPS -0.35 vs 1.71.
Abeona aims to reach profitability by mid-2026 with EPS of $1.71. Revenue is expected to grow strongly, doubling in one year. The stock trades cheap with a PE of 6.93, well below peers. Recent positive earnings beats show some progress.
The company missed earnings twice recently and cut guidance. It still loses money and faces risks from management changes. Revenue growth and profit targets may not be met soon.
The price is about 50% below our fair value near $13. Analysts expect revenue to double next year. We see risk in achieving profitability soon.
Breaks if: free cash flow yield remains below -10% next year
Breaks if: EPS falls below $1.71 by 2026-06-30
Breaks if: revenue growth falls below doubling by 2027-12-31
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario, as ABEO seeks to achieve profitability while expanding its commercial presence. The current thesis state reflects a cautious optimism due to recent revenue growth, but ongoing losses raise concerns.
The market appears to have priced in a low level of fragility, indicating that investors are not overly concerned about immediate risks. However, there is an expectations gap, suggesting that the market may not fully anticipate the challenges ABEO faces in achieving profitability.
Management is focused on the commercial launch and growth of ZEVASKYN, which has shown promising revenue increases. However, the company remains loss-making, and the near-term risk of missing earnings estimates is elevated, given the high miss rate in the industry.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company reported a 31% quarter-over-quarter increase in ZEVASKYN revenue. This growth supports the commercial launch and growth of ZEVASKYN. However, the latest earnings miss raises concerns about achieving profitability in the first half of 2026.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The thesis hinges on several factors, including management's ability to execute on profitability targets and the performance of key sector peers. Additionally, any changes in economic conditions, such as a weakening jobs report, could negatively impact ABEO's performance.
Over the next 1 to 3 years, ABEO's success will depend on its ability to navigate profitability challenges while leveraging sector momentum. Not investment advice.